SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of InMed Pharmaceuticals, Inc. (Nasdaq – INM)

BALA CYNWYD, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of InMed Pharmaceuticals, Inc. (“InMed” or the “Company”) (Nasdaq – INM) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Mentari Therapeutics, Inc. InMed shareholders are expected to own approximately 1.51% of the combined company.